Eris launches weekly shot of Semaglutide starting at ₹220 per shot
Eris Lifesciences, a leading Indian branded formulations company, today announced a breakthrough step in expanding access to…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Tag
Eris Lifesciences
Eris Lifesciences partners Natco Pharma to commercialise Semaglutide in India
CDSCO approval enables planned March 2026 launch targeting Type 2 diabetes management
Eris Lifesciences to consolidate its stake in Swiss Parenterals
Eris Lifesciences announced that its Board of Directors has approved the acquisition of the balance 30% stake in Swiss Parenterals…
Eris Lifesciences appoints Gopal Agrawal and Nita Borkar to leadership roles
New appointments to drive growth in domestic branded formulations business
Biocon Biologics sells branded formulations biz to Eris Lifesciences for INR12.42 bn
Includes portfolio of metabolics, oncology, and critical care products in India and a 10-year supply agreement with Eris
NPPA slashes prices on 33 FDCs drugs
This move affects pharma companies like JB Chemicals, Eris Lifesciences, Zydus Healthcare, Cipla, Sun Pharma, Sanofi India, and…
Biocon Biologics signs pact with Eris Lifesciences for divesture of dermatology and nephrology…
Total transaction value of the divestment is Rs 3,660 million, inclusive of working capital conveyed as part of the deal
Dr Reddy’s focuses on differentiated portfolio in key therapy areas for growth in India: GlobalData
DRL has earlier this month divested nine dermatology brands to Eris Lifesciences for Rs 2750 million ($33.3 million*). Within a…
Eris Lifesciences acquires nine dermatology brands from Dr Reddy’s for Rs 2,750 mn
Eris entered the dermatology segment through the acquisition of Oaknet Healthcare for Rs 6,500 million in May 2022 and…
Eris Lifesciences’s Q2FY23 revenue up 28 per cent YoY
EBITDA at Rs 1,514 million, with 32.9 per cent EBITDA margin; PAT stood at Rs 1,194 million, with 25.9 per cent PAT margin